After adjusting for confounders including age, weight, Histological types, tumor differentiation, tumor size, lymph node metastasis, and depth of stromal infiltration, the multivariate analysis identified tumor size (HR = 2.82, 95% CI: 1.32-4.04, p = 0.004), FIGO staging (HR = 3.64, 95% CI: 2.14-5.21, p = 0.007), and Hec1 expression (HR = 1.81, 95% CI: 1.22-3.18, p = 0.002) as independent risk factors for progression-free survival rates (see Table 4). This evidence concerns the gene NDC80 and neoplasm.